Published in Health Business Week, January 19th, 2007
These data offered are intended to provide as comprehensive an understanding of Mircera as is possible to assist the FDA in completing the review process. As a result of this action, the FDA has granted Roche a 3-month extension to the review period.
Roche is seeking an indication for Mircera in the treatment of anemia associated with chronic kidney disease (CKD) including patients on dialysis and not on dialysis. The BLA submitted to the FDA is based on data from all six studies that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.